Publications by authors named "V T Ivashkin"
The aim of this study was to investigate the levels of various tryptophan metabolites in patients with alcoholic liver disease (ALD) and metabolic-associated fatty liver disease (MAFLD) at different stages of the disease. The present study included 44 patients diagnosed with MAFLD, 40 patients diagnosed with ALD, and 14 healthy individuals in the control group. The levels of tryptophan and its 16 metabolites (3-OH anthranilic acid, 5-hydroxytryptophan, 5-methoxytryptamine, 6-hydroxymelatonin, indole-3-acetic acid, indole-3-butyric, indole-3-carboxaldehyde, indole-3-lactic acid, indole-3-propionic acid, kynurenic acid, kynurenine, melatonin, quinolinic acid, serotonin, tryptamine, and xanthurenic acid) in the serum were determined via high-performance liquid chromatography and tandem mass spectrometry.
View Article and Find Full Text PDFBackground: Sarcopenia and gut dysbiosis are common in cirrhosis. The aim is to study the correlations between the gut microbiota taxa and muscle mass level in cirrhosis.
Methods: The study included 40 cirrhosis patients including 18 patients with sarcopenia.
We aimed to systematize the results of published studies on the use of (SB) for the treatment of various liver disorders (CRD42022378050). Searches were conducted using PubMed and Scopus on 1 August 2022. The PubMed search was updated on 15 June 2024.
View Article and Find Full Text PDFGut Microbiota and Cytokine Profile in Cirrhosis.
J Clin Transl Hepatol
August 2024
Article Synopsis
- * Specific cytokines such as IL-1b, IL-6, and TNF-a were associated with both higher levels of harmful gut bacteria and the severity of cirrhosis symptoms like ascites, suggesting a connection between gut health and liver disease progression.
- * The results indicate that certain gut bacteria populations correlate directly with inflammatory cytokine levels, pointing to a potential link between gut dysbiosis and systemic inflammation in cirrhosis patients.
Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.
Clin Transl Gastroenterol
September 2024
Introduction: Increasing the effectiveness of eradication therapy is an important task in gastroenterology. The aim of this study was to evaluate the efficacy and safety of postbiotic containing inactivated (nonviable) Limosilactobacillus (Lactobacillus) reuteri DSM 17648 (Pylopass) as adjuvant treatment of Helicobacter pylori eradication in patients with functional dyspepsia (FD).
Methods: This randomized, double-blind, placebo-controlled, multicenter, parallel study included H.